Ventricular Assist Devices Market Forecasts to 2030 – Global Analysis By Product (Left Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist Device and Total Artificial Heart), Design, Type of Flow, Application, End User and By

Ventricular Assist Devices Market Forecasts to 2030 – Global Analysis By Product (Left Ventricular Assist Device, Right Ventricular Assist Device, Biventricular Assist Device and Total Artificial Heart), Design, Type of Flow, Application, End User and By Geography

According to Stratistics MRC, the Global Ventricular Assist Devices Market is accounted for $3.6 billion in 2024 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 19.6% during the forecast period. Mechanical pumps called Ventricular Assist Devices (VADs) help the ventricles pump blood to the body, hence supporting heart function. Patients who are not candidates for transplant surgery, have significant heart failure, or are awaiting a heart transplant frequently utilize them. VADs can be inserted into one or both ventricles, the most frequent being the left ventricle (LVAD), right ventricle (RVAD), or both (BiVAD). They raise the standard of living for patients, increase blood flow, and lessen cardiac strain.

According to the American Heart Association (AHA), the prevalence of heart failure is expected to increase at a significant growth rate by 2030 in the U.S., and is projected to reach over 8 million patients. In 2020, globally, more than 5.5 million individuals were affected by heart failure. Old-age people are at high risk of HF. Therefore, the increasing geriatric population has also been fueling the disease prevalence.

Market Dynamics:

Driver:

Global prevalence of heart failure

In wealthy nations, heart failure affects 1-2% of the population; by 2030, nearly 8 million Americans may be affected, according to forecasts. The rise in heart failure instances is a major factor driving the need for VADs. Moreover chronic illnesses that are common in aging populations, such as diabetes and hypertension, are the primary cause of the rise in heart failure patients Hence the demand for VADs is increased by the scarcity of available cardiac donors.

Restraint:

Risks associated with implantation

Increased bleeding risks are one of the surgical consequences associated with VAD implants, and anticoagulant medication may make matters worse. External parts such as controllers and power supplies can act as sites of entry for infections, which can cause serious problems and higher post-transplant mortality rates. Thrombosis is one device-related consequence that requires cautious anticoagulation level monitoring because it might cause strokes or pump failure. Furthermore, right ventricular dysfunction brought on by an increased stress on the heart may complicate patient outcomes and necessitate further procedures.

Opportunity:

Continuous innovations in VAD technology

Progress in technology has resulted in more robust and compact devices, enhancing the comfort and mobility of patients. Advances in biocompatibility have lowered risks of thrombosis and infections, which has lowered obstacles to patient adoption. VAD therapy is now more widely available to a larger range of patients thanks to the less invasive nature of miniaturization, which also makes recovery times quicker and implantation processes simpler.

Threat:

Inadequate reimbursement policies and insurance coverage

VADs require implantation procedures as well as post-operative care, which can be costly. Patients may be discouraged from choosing VAD therapy if they have to pay large out-of-pocket costs due to inadequate insurance coverage. Insufficient access to care can lead to postponed or abandoned medical interventions, deteriorating health outcomes and increasing long-term healthcare expenses, ultimately decreasing market demand for VADs.

Covid-19 Impact:

The COVID-19 pandemic negatively impacted the Ventricular Assist Devices (VAD) market by causing significant delays in elective surgeries and a reduction in device utilization. Lockdowns and travel restrictions led to fewer VAD transplants, as many patients postponed seeking treatment due to safety concerns. This resulted in decreased demand for VADs, affecting revenue for manufacturers and healthcare providers. However, as restrictions eased, a rebound in patient visits and procedures is anticipated, potentially revitalizing market growth in subsequent years.

The biventricular assist devices segment is expected to be the largest during the forecast period

The biventricular assist devices segment is expected to be the largest during the forecast period owing to increased demand and advancements in BiVAD technology, such as pneumatically driven systems that improve device performance and usefulness in total artificial heart (TAH) transplant scenarios. Better hemodynamic support, improved quality of life, increased survival rates, and more patient and physician acceptance are all achieved by BiVADs.

The bridge-to-transplant segment is expected to have the highest CAGR during the forecast period

The bridge-to-transplant segment is expected to have the highest CAGR during the forecast period owing to its vital function in keeping patients stable while they await heart transplants. VADs improve patient outcomes by providing necessary mechanical support for a period of two to six months. A greater understanding of the effectiveness of BTT therapy promotes its broader use in the treatment of heart failure.

Region with largest share:

North America is expected to have the largest market share over the projection period due to the growing rate of heart failure in North America combined with technological developments in medical devices has raised demand for valve assist devices (VADs) as destination and bridge-to-transplant therapies. Moreover VADs offer a vital substitute in the event that there are insufficient donor hearts available for transplantation, assisting patients in surviving either permanently or while they wait for a transplant.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest rate of growth during the forecast period owing to increased investment in modern medical technology and healthcare infrastructure by China, India, Japan, and South Korea is contributing to the growing use of VADs. The need for sophisticated heart failure management solutions is being driven by rising awareness and enhanced diagnostic capabilities. The Asia Pacific VAD market is expanding as a result of technological developments that include the development of smaller, more effective devices with fewer issues.

Key players in the market

Some of the key players in Ventricular Assist Devices Market include Abiomed Inc., BiVACOR Inc, Abbott Laboratories, Berlin Heart GmbH, Calon Cardio, Medtronic PLC, SynCardia Systems LLC, Terumo Corporation, Jarvik Heart Inc., ReliantHeart, Inc. and Sun Medical Technology Research Corp .

Key Developments:

In September 2024, Abbott announced the findings of a new survey among leading infectious disease experts around the world on the state of pandemic preparedness and found that while most agree that preparation has improved since the COVID-19 pandemic.

In September 2024, Abbott announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. Lingo is based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by more than 6 million people with diabetes globally.

In September 2024, Medtronic plc announced at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several software, hardware, and imaging innovations.

Products Covered:
• Left Ventricular Assist Device
• Right Ventricular Assist Device
• Biventricular Assist Device
• Total Artificial Heart

Designs Covered:
• Implantable Ventricular Assist Devices
• Transcutaneous Ventricular Assist Devices

Type of Flows Covered:
• Pulsatile Flow VAD
• Continuous Flow VAD

Applications Covered:
• Bridge-to-Transplant
• Destination Therapy
• Bridge-to-Recovery
• Bridge-to-Candidacy

End Users Covered:
• Hospitals
• Cardiac Surgery Centers
• Home Care Agencies
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements